New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis

Cell Reports

Volumn 13, Issue 4, 2015, Pages 840-853

  Rambow, Florian ^a,b,c,d   Job, Bastien ^e   Petit, Valérie ^a,b,c,d   Gesbert, Franck ^a,b,c,d   Delmas, Véronique ^a,b,c,d   Seberg, Hannah ^f   Meurice, Guillaume ^e   Van Otterloo, Eric ^f   Dessen, Philippe ^e   Robert, Caroline ^e   Gautheret, Daniel ^e   Cornell, Robert A ^f   Sarasin, Alain ^g   Larue, Lionel ^a,b,c,d  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c Centre National de la Recherche Scientifique   (France)

^d Equipe Labellisee e Ligue Nationale contre le Cancer   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF IOWA   (United States)

^g Gustave Roussy Comprehensive Cancer Institute   (France)

Author keywords

Breast; Colon; Ewing sarcoma; Glioblastoma; Liver; Lung; Melanoma; MiRNA; Neuroblastoma; Ovary; Phenotype switching; Survival; Transcriptome

Indexed keywords

LYMPHOID ENHANCER FACTOR 1; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 10A 5P; MICRORNA 211 3P; MICRORNA 211 5P; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR SOX10; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ALX1 GENE; ARTICLE; CANCER CELL; CANCER LOCALIZATION; CANCER SURVIVAL; CELL FUNCTION; CELL INVASION; CELL LINEAGE; CELL MIGRATION; CONTROLLED STUDY; DLX2 GENE; GAS7 GENE; GENE; IN VITRO STUDY; LEF1 GENE; MATHEMATICAL MODEL; MELANOMA; MITF GENE; OVERALL SURVIVAL; PAX3 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMILARITY CORE ANALYSIS; SOX10 GENE; TFAP2A GENE; BIOLOGY; GENETICS; HUMAN; PROCEDURES;

CELL LINEAGE; COMPUTATIONAL BIOLOGY; HUMANS; MELANOMA; MICRORNAS; TRANSCRIPTOME;

EID: 84945530165     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.037     Document Type: Article

References (58)

1. Achim K., Salminen M., Partanen J. Mechanisms regulating GABAergic neuron development. Cell. Mol. Life Sci. 2014, 71:1395-1415.
2. Akavia U.D., Litvin O., Kim J., Sanchez-Garcia F., Kotliar D., Causton H.C., Pochanard P., Mozes E., Garraway L.A., Pe'er D. An integrated approach to uncover drivers of cancer. Cell 2010, 143:1005-1017.
3. Alonso-Curbelo D., Riveiro-Falkenbach E., Pérez-Guijarro E., Cifdaloz M., Karras P., Osterloh L., Megías D., Cañón E., Calvo T.G., Olmeda D., et al. RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. Cancer Cell 2014, 26:61-76.
4. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
5. Basu A., Bodycombe N.E., Cheah J.H., Price E.V., Liu K., Schaefer G.I., Ebright R.Y., Stewart M.L., Ito D., Wang S., et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 2013, 154:1151-1161.
6. Bell R.E., Khaled M., Netanely D., Schubert S., Golan T., Buxbaum A., Janas M.M., Postolsky B., Goldberg M.S., Shamir R., Levy C. Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J. Invest. Dermatol. 2014, 134:441-451.
7. Betancur P., Bronner-Fraser M., Sauka-Spengler T. Genomic code for Sox10 activation reveals a key regulatory enhancer for cranial neural crest. Proc. Natl. Acad. Sci. USA 2010, 107:3570-3575.
8. Bogunovic D., O'Neill D.W., Belitskaya-Levy I., Vacic V., Yu Y.L., Adams S., Darvishian F., Berman R., Shapiro R., Pavlick A.C., et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. USA 2009, 106:20429-20434.
9. Carreira S., Goodall J., Denat L., Rodriguez M., Nuciforo P., Hoek K.S., Testori A., Larue L., Goding C.R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006, 20:3426-3439.
10. Chao C.C., Chang P.Y., Lu H.H. Human Gas7 isoforms homologous to mouse transcripts differentially induce neurite outgrowth. J. Neurosci. Res. 2005, 81:153-162.
11. Cheli Y., Ohanna M., Ballotti R., Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 2010, 23:27-40.
12. Cheli Y., Giuliano S., Botton T., Rocchi S., Hofman V., Hofman P., Bahadoran P., Bertolotto C., Ballotti R. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011, 30:2307-2318.
13. Cheung H.W., Cowley G.S., Weir B.A., Boehm J.S., Rusin S., Scott J.A., East A., Ali L.D., Lizotte P.H., Wong T.C., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 2011, 108:12372-12377.
14. Dancik G.M., Ru Y., Owens C.R., Theodorescu D. A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res. 2011, 71:7398-7409.
15. Daniele T., Hurbain I., Vago R., Casari G., Raposo G., Tacchetti C., Schiaffino M.V. Mitochondria and melanosomes establish physical contacts modulated by Mfn2 and involved in organelle biogenesis. Curr. Biol. 2014, 24:393-403.
16. Domcke S., Sinha R., Levine D.A., Sander C., Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 2013, 4:2126.
17. Ertel A., Verghese A., Byers S.W., Ochs M., Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol. Cancer 2006, 5:55.
18. Felicetti F., Errico M.C., Bottero L., Segnalini P., Stoppacciaro A., Biffoni M., Felli N., Mattia G., Petrini M., Colombo M.P., et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008, 68:2745-2754.
19. Friedman E.B., Shang S., de Miera E.V., Fog J.U., Teilum M.W., Ma M.W., Berman R.S., Shapiro R.L., Pavlick A.C., Hernando E., et al. Serum microRNAs as biomarkers for recurrence in melanoma. J. Transl. Med. 2012, 10:155.
20. Gillet J.P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. USA 2011, 108:18708-18713.
21. Gillet J.P., Varma S., Gottesman M.M. The clinical relevance of cancer cell lines. J. Natl. Cancer Inst. 2013, 105:452-458.
22. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 2010, 28:2777-2783.
23. Harris M.L., Baxter L.L., Loftus S.K., Pavan W.J. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res. 2010, 23:496-513.
24. Hoek K.S., Goding C.R. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 2010, 23:746-759.
25. Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006, 19:290-302.
26. Hoek K.S., Eichhoff O.M., Schlegel N.C., Döbbeling U., Kobert N., Schaerer L., Hemmi S., Dummer R. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008, 68:650-656.
27. Hung F.C., Cheng Y.C., Sun N.K., Chao C.C. Identification and functional characterization of zebrafish Gas7 gene in early development. J. Neurosci. Res. 2013, 91:51-61.
28. Jönsson G., Busch C., Knappskog S., Geisler J., Miletic H., Ringnér M., Lillehaug J.R., Borg A., Lønning P.E. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 2010, 16:3356-3367.
29. Juriloff D.M., Harris M.J. Mouse models for neural tube closure defects. Hum. Mol. Genet. 2000, 9:993-1000.
30. Kanemaru H., Fukushima S., Yamashita J., Honda N., Oyama R., Kakimoto A., Masuguchi S., Ishihara T., Inoue Y., Jinnin M., Ihn H. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 2011, 61:187-193.
31. Kim N., He N., Yoon S. Cell line modeling for systems medicine in cancers (review). Int. J. Oncol. 2014, 44:371-376.
32. Koludrovic D., Davidson I. MITF, the Janus transcription factor of melanoma. Future Oncol. 2013, 9:235-244.
33. Larue L., Delmas V. The WNT/Beta-catenin pathway in melanoma. Front. Biosci. 2006, 11:733-742.
34. Levy C., Khaled M., Robinson K.C., Veguilla R.A., Chen P.H., Yokoyama S., Makino E., Lu J., Larue L., Beermann F., et al. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 2010, 141:994-1005.
35. Li J., Dong J., Zhang Z.H., Zhang D.C., You X.Y., Zhong Y., Chen M.S., Liu S.M. miR-10a restores human mesenchymal stem cell differentiation by repressing KLF4. J. Cell. Physiol. 2013, 228:2324-2336.
36. Loftus S.K., Larson D.M., Baxter L.L., Antonellis A., Chen Y., Wu X., Jiang Y., Bittner M., Hammer J.A., Pavan W.J. Mutation of melanosome protein RAB38 in chocolate mice. Proc. Natl. Acad. Sci. USA 2002, 99:4471-4476.
37. Luo H., Sun S., Li P., Bu D., Cao H., Zhao Y. Comprehensive characterization of 10,571 mouse large intergenic noncoding RNAs from whole transcriptome sequencing. PLoS ONE 2013, 8:e70835.
38. Mann G.J., Pupo G.M., Campain A.E., Carter C.D., Schramm S.J., Pianova S., Gerega S.K., De Silva C., Lai K., Wilmott J.S., et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J. Invest. Dermatol. 2013, 133:509-517.
39. Masters J.R. Human cancer cell lines: fact and fantasy. Nat. Rev. Mol. Cell Biol. 2000, 1:233-236.
40. Medic S., Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit. Rev. Biochem. Mol. Biol. 2009, 44:85-97.
41. Meghnani V., Vetter S.W., Leclerc E. RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line. Biochim. Biophys. Acta 2014, 1842:1017-1027.
42. Melnikova V.O., Bar-Eli M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol. Ther. 2008, 7:997-1003.
43. Merlo G.R., Zerega B., Paleari L., Trombino S., Mantero S., Levi G. Multiple functions of Dlx genes. Int. J. Dev. Biol. 2000, 44:619-626.
44. Mobley A.K., Braeuer R.R., Kamiya T., Shoshan E., Bar-Eli M. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev. 2012, 31:621-632.
45. Raimbourg Q., Perez J., Vandermeersch S., Prignon A., Hanouna G., Haymann J.P., Baud L., Letavernier E. The calpain/calpastatin system has opposing roles in growth and metastatic dissemination of melanoma. PLoS ONE 2013, 8:e60469.
46. Raposo G., Marks M.S. Melanosomes--dark organelles enlighten endosomal membrane transport. Nat. Rev. Mol. Cell Biol. 2007, 8:786-797.
47. Sáez-Ayala M., Montenegro M.F., Sánchez-Del-Campo L., Fernández-Pérez M.P., Chazarra S., Freter R., Middleton M., Piñero-Madrona A., Cabezas-Herrera J., Goding C.R., Rodríguez-López J.N. Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell 2013, 24:105-119.
48. Sandberg R., Ernberg I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc. Natl. Acad. Sci. USA 2005, 102:2052-2057.
49. Sauka-Spengler T., Bronner-Fraser M. A gene regulatory network orchestrates neural crest formation. Nat. Rev. Mol. Cell Biol. 2008, 9:557-568.
50. Segura M.F., Belitskaya-Levy I., Rose A.E., Zakrzewski J., Gaziel A., Hanniford D., Darvishian F., Berman R.S., Shapiro R.L., Pavlick A.C., et al. Melanoma microRNA signature predicts post-recurrence survival. Clin. Cancer Res. 2010, 16:1577-1586.
51. Stinson S., Lackner M.R., Adai A.T., Yu N., Kim H.J., O'Brien C., Spoerke J., Jhunjhunwala S., Boyd Z., Januario T., et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci. Signal. 2011, 4:ra41.
52. Strub T., Giuliano S., Ye T., Bonet C., Keime C., Kobi D., Le Gras S., Cormont M., Ballotti R., Bertolotto C., Davidson I. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 2011, 30:2319-2332.
53. Uva P., Lahm A., Sbardellati A., Grigoriadis A., Tutt A., de Rinaldis E. Comparative Membranome expression analysis in primary tumors and derived cell lines. PLoS ONE 2010, 5:e11742.
54. Uz E., Alanay Y., Aktas D., Vargel I., Gucer S., Tuncbilek G., von Eggeling F., Yilmaz E., Deren O., Posorski N., et al. Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. Am. J. Hum. Genet. 2010, 86:789-796.
55. van Staveren W.C., Solís D.Y., Hébrant A., Detours V., Dumont J.E., Maenhaut C. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells?. Biochim. Biophys. Acta 2009, 1795:92-103.
56. Widmer D.S., Cheng P.F., Eichhoff O.M., Belloni B.C., Zipser M.C., Schlegel N.C., Javelaud D., Mauviel A., Dummer R., Hoek K.S. Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res. 2012, 25:343-353.
57. Zhang J., Hagopian-Donaldson S., Serbedzija G., Elsemore J., Plehn-Dujowich D., McMahon A.P., Flavell R.A., Williams T. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 1996, 381:238-241.
58. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103:9136-9141.